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Background: Metabolic syndrome is a set of disorders that increases the risk of developing cardiovascular disease.
The primary target of treatment of patients with metabolic syndrome is therapeutic lifestyle change. Numerous
preclinical study have reported positive effects of chungkookjang in in vivo models of diabetes and obesity, but
there is a paucity of controlled clinical trials on variables of metabolic syndrome in obese subjects. Thus, the
objective of this trial is to examine the effect of chungkookjang compared to placebo on variables of metabolic
syndrome in overweight/obese subjects.
Methods: This double-blind randomized controlled crossover trial will be conducted on 120 overweight/obese
subjects; aged 19–29 years. Subjects will be recruited from the Chonbuk National University, Jeonju, South Korea.
Enrolled subjects will be randomly assigned to two groups of equal number; one group received 35 g of chungkookjang
(n = 60) and the other group received placebo (n = 60) on a regular daily basis for 12 weeks. After a 12-week washout
period, the groups will be crossed over. In addition to anthropometric measures and blood pressure, glucose parameter,
lipid profile, adipocytokine, and carnitine assay will be determined at baseline and 12 week. Also, safety will be assessing
by measuring total bilirubin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, total protein,
albumin, blood urea nitrogen, creatinine, and creatine kinase at baseline and 12 weeks. 24-hour dietary recalls were
collected at the baseline and at the end of the trial.
Discussion: This trial will evaluate the effects of chungkookjang on variables of metabolic syndrome in
overweight/obese subjects. The results of this study may contribute to the reduction of risk factor for
metabolic syndrome caused by obesity.
Trial registration: Clinical trials NCT01811511.
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The prevalence of obesity has increased worldwide over
the past decades [1,2], although more recent data suggest
a slowing of this trend. The rising rates of obesity in
children and adults have been accompanied by an increase
in the co-occurrence of obesity-associated metabolic
abnormalities known as the metabolic syndrome (Met-S).
The prevalence of Met-S is increasing; it currently affects
22.1% of men and 27.8% of women in Korea [3,4].
The clustering of major components of the syndrome,
including obesity, dyslipidemia, hypertension, and insulin
resistance, has been demonstrated in youth [5,6], and
clustering of these risk factors has also been shown
to track into early adulthood. These obese youth are
a high-risk population to target for screening, prevention,
and intervention for Met-S [5,6].
Conclusions in nutritional intervention studies are
frequently drawn from epidemiological studies, but
there are affected by many possible confounding factors.
Unlike laboratory animals, human beings cannot be fed
over a long time; thus most nutritional intervention
studies are short to medium term and focus on surrogate
parameters. On the other hand, although the preferred
treatment for Met-S is lifestyle modification including
exercise and nutrition therapy [7,8], the challenge is the
multitude of risk factors and the high prevalence of
obesity. But there are difficult to approach in typically
clinic visits. Furthermore, in the large scale trials, subjects
often struggle with adopting lifestyle changes to derive
siginificant results, but it is difficult to control the subjects
by physician or investigators.
Soybeans contain various nutritious and functional
components such as isoflavonoids besides soy protein
which are helpful in protecting against metabolic diseases
such as obesity and type 2 diabetes [9]. Fermenting soybean
such as chungkookjang (CKJ) may be enhance the
functionality of soybeans to protect against metabolic
disease. Korean traditional CKJ is a good fermented
soybean product for use as a functional food. However,
traditional CKJ did not recognized as a functional food in
Korea. Currently, the non-clinical data on effects of CKJ
have been reported from in vivo and in vitro studies
[10-18] but there is paucity the controlled clinical trials on
variables of Met-S. Our previous study have revealed that
traditionally made CKJ from Sunchang district of Jeolla
province, Korea showed potential anti-atherosclerotic
effects in overweight/obese subjects [19]. It has also been
reported that traditional CKJ (made from Sunchang
district of Jeolla province, Korea) improves insulinotropic
action and hepatic insulin sensitivity in diabetic rats [16,17].
However, CKJ intake in Korean youth is gradually
decreased due to distinctive flavor of CKJ. Therefore, the
present study will be conducted by the easy-to-eat
freeze-dried CKJ pills. The CKJ shows distinctive flavorcharacteristics. For this reason, we used cinnamon as
flavoring agent to make it palatable. The purpose of this
study is to evaluate the effect of CKJ compared to placebo
on variables of Met-S in overweight/obese subjects.Methods and design
Objective
The objectives of this RCT are to study whether the CKJ
can improve the Met-S in overweight/obese subjects.Primary objective
To evaluate the efficacy of the CKJ on anthropometric
parameter in overweight/obese subjects after 12 weeks
of consumption.Secondary objectives
To evaluate the following factors in overweight or obese





E) carnitine assayDesign and setting
This is a 12 weeks, randomized, double-blinded, placebo-
controlled crossover study. From February 2013 to
December 2013, Obesity Research Center of Chonbuk
National University and Chonbuk National University
Hospital Clinical Trial Center in Korea will participate in
this study. Recruitment will therefore be expected to be
completed within the study period. To recruit the
participants, we will advertise in the bulletin board
and on the internet homepage of Chonbuk National
University. Eligible participants will be randomly allocated
into 2 group (the CKJ or placebo group) with 1:1 allocation
ratio and receive treatment for 12 weeks. After a 12-week
washout period, the groups will be crossed over. The
evaluation of participants and the analysis of the results
will be performed by professional blinded to the group
allocation. Written consent will be obtained from each
participant before the start of this study. Our study plan is
summarized in Figure 1.Inclusion criteria
Subjects will be included if they meet the following
criteria: (1) men and women between 19 and 29 years of
age; (2) overweight/obese (body mass index of 23 kg/m2
or a waist circumference of 90 cm for men, 80 cm for
women); (3) ability to give informed consent.
Figure 1 Flow diagram for study. Summary of the study flow.
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The exclusion criteria for the study were: (1) severe heart
disease (heart failure, angina, myocardial infarction, valvular
heart disease, arrhythmias); (2) severe cerebrovascular disease
(stroke, hemorrhage); (3) acute or chronic inflammatory
disease; (4) malignant tumor (leukemia, lymphoma);
(5) diagnosis of type 1 and type 2 diabetes or fasting
glucose ≥ 126 mg/Dl; (6) Systolic pressure ≥ 160 mmHg,
diastolic pressure ≥ 100 mmHg; (7) hereditary hyper-
lipidemia; (8) allergic or hypersensitive response to any of
the ingredients in the test products; (9) a history of disease
that could interfere with the test products or impede theirabsorption such as gastrointestinal disease or gastrointes-
tinal surgery; (10) under antipsychotic drugs therapy within
past 2 months; (11) participation in any other clinical trials
within past 2 months; (12) abnormal hepatic liver function
or renal disease (acute/chronic renal failure or nephrotic
syndrome); (13) laboratory test, medical or psychological
conditions that might interfere with successful participation
in the study based on the judgment of the investigators.
Randomization and allocation concealment
After enrollment, subjects will be randomly assigned to
one of the two groups, either the CKJ group or placebo
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Randomization will be performed at a site remote from
trial location. Random numbers will be generated by a
computerized random-number generator through the
block-randomization method of a software program
(Excel, Microsoft Office 2007) for sequence generation. At
the time of randomization subjects will draw an envelope.
Each envelope contains a number that is concealed to the
treatment allocation. Randomization sequence and alloca-
tion will be concealed to all study subjects, research staff,
investigators and pharmacists until completion of the study.
The allocation list will be protected by password access
files and held by a non-investigator independent. In the
event of an emergency medical situation the individual’s
randomization code and group allocation can be identify.
Intervention
Subjects will be assigned CKJ or placebo group for
12 weeks. CKJ treatment group will be received 35 g
CKJ (equivalent to 70 g of fresh CKJ) per day and they
should consume a pack of the CKJ with three times a
day after meals. The selection of the doses investigated in
this study was based upon efficacy and safety data obtained
from a previous human study [19]. Chungkookjang is
provided by Sunchang Research Center for Fermentation
Microbes (Sunchang, Republic of Korea), freeze-dried
using a freeze-dryer, and then made into pills (Imshil
Herbal Medicine Co., Imshil, Republic of Korea). Placebos
were made with the same taste, appearance, and energy
content but without the principal ingredient that was
present in the CKJ. CKJ/placebo pills were provided to
subjects every 6 weeks.
Outcome measures
Primary outcome measurement
The primary outcome is the anthropometric parameter
(weight, body mass index, body fat mass, percentage body
fat, lean body mass, waist circumference, hip circumference,
and waist to hip ratio).
Secondary outcome measurements
Secondary outcomes will be blood pressure, glucose par-
ameter (fasting glucose, HbA1c, insulin, gamma-glutamyl
transferase [GGT]), lipid profile (total cholesterol,
triglycerides, high-density lipoprotein-cholesterol [HDL-C],
low-density lipoprotein-cholesterol [LDL-C], free fatty acid,
apolipoprotein A1 [Apo A1], apolipoprotein B [Apo B],
high-sensitivity C-reactive protein [hs-CRP]), adipocytokine
(leptin, adiponectin, ghrelin), and carnitine assay. These
biomarkers will be checked at weeks 0 (baseline) and 12
(end of the trial). 24-hour dietary recalls were collected at
the baseline and at the end of the trial. The schedule of
assessments is presented in Table 1.Statistical analysis and sample size
Baseline data and outcomes data
Statistical analysis will be performed using SAS version
9.3 for Windows (SAS Institute, Cary, NC, USA). Data
will be presented as mean values and standard deviation
(SD). The Chi-square test will be performed to determine
differences at baseline in frequencies of categorized vari-
ables between the groups. A linear mixed-effects model will
be applied to repeated-measures data for each continuous
outcome variable. Fixed effects will be included treatment
group, treatment visit, and interaction between treatment
group and visit. When the analysis of variance indicated
significant differences among groups, post hoc test
(Turkey’s test) will be used to separate the differences
between groups before and after the 12-week intervention
period. A value of p < 0.05 will be considered statistically
significant.Compliance
The CKJ or placebo remaining after each visit will be
quantified in order to enhance medication compliance.
Subjects whose compliance with the CKJ or placebo
is ≤ 70% of the total dose will be considered to have
dropped-out.Sample size
Sample size calculation is performed; primary outcome
measure will be the percentage body fat, whereby 1.1% is
assumed a clinically relevant difference between the two
groups, with a standard deviation of 2.78%, alpha set on
5% and power on 80%. This resulted in a required
number of 50 subjects in each group. Assuming a dropout
rate of 20%, a total of 120 subjects will be enrolled in
this trial.Adverse events
All unexpected adverse events related to CKJ intake will
be reported to the investigator by subjects and write on
the individual case report form by the investigator. Safety
will be assessed by the reporting of clinical laboratory
tests, vital sign measurements, and adverse events. Clinical
laboratory tests, including blood test (white blood cell
[WBC], red blood cell [RBC], hemoglobin, hematocrit,
platelets count, total bilirubin [TB], alkaline phosphatase
[ALP], alanine transaminase [ALT], aspartate aminotrans-
ferase [AST], total protein, albumin, blood urea nitrogen
[BUN], creatinine, creatine kinase [CK]), and urine test
(specific gravity, pH, nitrite, protein, glucose, ketone,
urobilinogen, bilirubin, microscopic RBC/WBC) will be
determined at weeks 0 (baseline) and 12 (end of the trial).
Vital signs of each subject will be checked with monitoring
of AEs (any AEs related to CKJ intake) after each visit.
Table 1 A brief study schedule at every visit
Crossover design
Screening Baseline Follow up
Visit 1 Visit 2, 5 Visit 3, 6 Visit 4, 7 (Visit 8)
D-28 Week 0 Week 6 Week 12 Week 24
~D-1 D0 D42 D84 D168
Informed consent form ◯
Demographic information taking1 ◯
Medical history taking ◯
Inclusion/exclusion criteria check ◯ ◯
Physician examination2 ◯ ◯ ◯
Drinking/smoking taking status3 ◯ ◯
Vital sign measurement ◯ ◯ ◯ ◯ ◯
Concomitant drugs check ◯ ◯ ◯ ◯ ◯
Anthropometric measures4 ◯ ◯ ◯ ◯
Glucose parameter5 ◯ ◯
Lipid profile6 ◯ ◯
Adipocytokine7 ◯ ◯
Carnitine assay ◯ ◯
Laboratory test8 ◯ ◯
Study product distribution ◯ ◯
Compliance checking ◯ ◯
Adverse event monitoring ◯ ◯ ◯ ◯
Diet, physical exercisecounseling9 ◯ ◯ ◯ ◯
◯: Item need to be performed during the visit.
1 Sex, date of birth, age, contact address and phone number.
2 Include present illness, past history taking.
3,9Risk factors such as alcohol drinking, smoking, severe exercise and other dietary supplement intake will be managed.
4 weight, body mass index, body fat mass, percentage body fat, lean body mass, waist circumference, hip circumference, and waist to hip ratio.
5 fasting glucose, HbA1c, insulin, gamma-glutamyl transferase (GGT).
6 total cholesterol, triglycerides, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), free fatty acid, apolipoprotein
A1 (Apo A1), apolipoprotein B (Apo B), high-sensitivity C-reactive protein (hs-CRP).
7 leptin, adiponectin, ghrelin.
8 Blood test (white blood cell [WBC], red blood cell [RBC], hemoglobin, hematocrit, platelets count, total bilirubin [TB], alkaline phosphatase [ALP], alanine
transaminase [ALT], aspartate aminotransferase [AST], total protein, albumin, blood urea nitrogen [BUN], creatinine, creatine kinase [CK]), urine test (specific
gravity, pH, nitrite, protein, glucose, ketone, urobilinogen, bilirubin, microscopic RBC/WBC).
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The study protocol and the written informed consent
were approved by the Functional Foods Institutional
Review Board of Chonbuk National University Hospital
(CUH IRB 2013-01-002). Each subject will be notified
regarding the study protocol. Written informed consent
will be obtained from each subject.
Discussion
The aim of this study is to evaluate the efficacy of the
CKJ on the Met-S. For this purpose, the ability of the
CKJ to variables the Met-S will be assessed in 120
overweight/obese subjects.
In this study, we expect that the CKJ effectively reduction
of risk factor for Met-S. Some studies have investigated theaction of CKJ on the Met-S. The clinical trial for Met-S
enhancement of CKJ has not been performed up to
this time. However, numerous studies have reported
from in vivo and in vitro studies [10-19]. Therefore, if
this study will be successfully performed, the CKJ
may offer beneficial effects in reducing of risk factor for
Met-S. And these results will have important implications
for the design of sustainable cost-effective health services
for people with Met-S caused by obesity. In addition, this
study will be the groundwork for the larger scale RCT. To
draw confirmative conclusion about the therapeutic efficacy
and safety of the CKJ, a full-scale RCT will be performed.Competing interests
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